NAT1 Antibody (S09-8F5)

Western Blot: NAT1 Antibody (S09-8F5) [NBP3-15062] - Western blot detection of NAT1 in C6, 3T3, Hela cell lysates using NAT1 Rabbit mAb (1:1000 diluted). Predicted band size: 34kDa. Observed band size: 34kDa.

• Reactivity: Hu
• Applications: WB, ELISA, ICC/IF, IHC
• Clone: S09-8F5
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

NAT1 Antibody (S09-8F5) Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: A synthetic peptide of human NAT1 (Uniprot#: P18440)
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: NAT1
• Purity: Affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/Immunofluorescence 20 ug/mL
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 2.5 ug/ml
  • Western Blot
• Theoretical MW: 34 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 50nM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.05% BSA
• Preservative: 0.01% Sodium Azide
• Purity: Affinity purified

Alternate Names for NAT1 Antibody (S09-8F5)

• AAC1N-acetyltransferase type 1
• Arylamide acetylase 1
• arylamine N-acetyltransferase 1
• EC 2.3.1.5
• MNAT
• Monomorphic arylamine N-acetyltransferase
• N-acetyltransferase 1 (arylamine N-acetyltransferase)
• NAT-1
• NATI

Background

NAT1 is a gene that codes for a protein that helps in the detoxification of various hydrazine and arylamine drugs as well as to bioactivate several carcinogens and is 290 amino acids long with a weight of approximately 34 kDa. Current studies are being done on several diseases and disorders related to this gene including neural tube defect, drug-induced hepatitis, talipes equinovarus, spina bifida, multiple chemical sensitivity, malignant pleural mesothelioma, non-Hodgkin lymphoma, cleft palate, familial adenomatous polyposis, substance abuse, orofacial cleft, peptic ulcer, lymphoblastic leukemia, systemic lupus erythematosus, cystic fibrosis, lupus erythematosus, Hodgkin's lymphoma, inflammatory bowel disease, and motor neuron disease. NAT1 has also been shown to have interactions with NAA10, SNTA1, SYP1A2, CYP2A6, and XDH in pathways such as the arylamine metabolism, acetylation, and drug metabolism pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: NAT1